Skip to main content
Fig. 4 | BMC Biology

Fig. 4

From: DDX39B interacts with the pattern recognition receptor pathway to inhibit NF-κB and sensitize to alkylating chemotherapy

Fig. 4

DDX39B modulates resistance to TMZ in GBM. a Clonogenic assay in four independent U87 sh-DDX39B-expressing clones or a non-targeting control treated with vehicle or TMZ at indicated concentrations. Data show mean value from triplicate samples relative to untreated cells, ± SD, repeated. b Trypan blue assay in GBM44 GCSs stably expressing sh-DDX39B or non-targeting control treated with TMZ (100 μM, 72 h). Data show percentage of dead cells normalized to vector control from triplicate samples, ± SD, repeated. Inset: IB with anti-DDX39B. c Clonogenic assay in U87 cells stably expressing EV or DDX39B treated with vehicle or TMZ at the indicated concentration. Data show mean value relative to untreated cells, ± SD, repeated. Inset: IB with anti-DDX39B. d Trypan blue assay in GBM34 GSCs stably expressing EV or DDX39B treated with vehicle or TMZ (100 μM, 72 h). Data show percent dead cells from triplicate samples ± SD, normalized to EV-expressing cells treated with vehicle, repeated with similar results. *P < 0.05, **P < 0.01 (two-tailed t test)

Back to article page

BMC Biology

ISSN: 1741-7007

Contact us